OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Video

August 21, 2020

Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs

Author(s):

Pankti Reid, MD, MPH

In Partnership With:

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Pankti Reid, MD, MPH, rheumatologist, assistant professor ​of medicine, University of Chicago Medicine, discusses remaining challenges regarding the management of immune-related adverse effects (irAEs).

Although the advent of multidisciplinary toxicity teams has facilitated efficient evaluation and management of multi-organ irAEs, challenges remain, Reid says. Moreover, optimization of diagnostic tools and identification of efficacious therapies beyond steroids, is needed.

Systemic steroids, which are currently the standard of care for managing irAEs, are associated with significant toxicities of their own, explains Reid. Additionally, managing irAEs often calls for high-dose steroids given over a long period of time.

As such, developing steroid-sparing regimens is necessary to reduce the potential impact of treatment for irAEs, concludes Reid.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer
Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma
Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
Advertisement
Multidisciplinary Collaboration in Early-Stage NSCLC | Image by Ashling Wahner & MJH Life Sciences Using AI
June 4th 2025

Multidisciplinary Collaboration Is Essential in Early-Stage NSCLC

Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, the University of California San Diego Health; Rachel N. Grisham, MD, associate attending physician, Memorial Sloan Kettering Cancer Center; Benjamin Herzberg, MD, assistant professor, medicine, Columbia University Medical Center, oncologist, Herbert Irving Comprehensive Cancer Center; Kelly McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA Health’s David Geffen School of Medicine; Gregory Roloff, MD, hematologist/oncologist, the University of Chicago Medicine
March 31st 2025

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

Pedro Barata, MD, MSc, FACP
March 5th 2025

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois
August 12th 2024

ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

Marina Chiara Garassino, MD, from the University of Chicago
September 8th 2024

TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC

Related Content
Advertisement
Multidisciplinary Collaboration in Early-Stage NSCLC | Image by Ashling Wahner & MJH Life Sciences Using AI
June 4th 2025

Multidisciplinary Collaboration Is Essential in Early-Stage NSCLC

Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, the University of California San Diego Health; Rachel N. Grisham, MD, associate attending physician, Memorial Sloan Kettering Cancer Center; Benjamin Herzberg, MD, assistant professor, medicine, Columbia University Medical Center, oncologist, Herbert Irving Comprehensive Cancer Center; Kelly McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA Health’s David Geffen School of Medicine; Gregory Roloff, MD, hematologist/oncologist, the University of Chicago Medicine
March 31st 2025

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

Pedro Barata, MD, MSc, FACP
March 5th 2025

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois
August 12th 2024

ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

Marina Chiara Garassino, MD, from the University of Chicago
September 8th 2024

TROP2 Membrane Ratio Effectively Predicts Dato-DXd Outcomes in NSCLC

Latest Conference Coverage

Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo

Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML

Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL

Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact